Research Collaboration Sample Clauses

Research Collaboration. Joint research programs will be developed, which will lead to joint research projects, joint publications, and faculty and graduate student exchanges. Traveling and accommodation expenses for exchanges or visits involving faculty will be the responsibility of the Institution, or Faculty or Department of that Institution, whose staff are undertaking the exchange or visit. The initial funding for research, faculty exchange and graduate student research projects will be the responsibility of each institution, but the Institutions will endeavor to develop joint funding opportunities in the future (e.g. US NSF, USDA and other relevant federal agencies and private institutions). Faculty of both Institutions will identify projects of mutual interest. The specific areas of research collaboration will initially focus on

Research Collaboration. (a) GSK hereby grants to Anacor a non-exclusive, non-royalty bearing license under the GSK IP, solely as and to the extent necessary or important to conduct activities for which Anacor is responsible under the Research Plans during the Research Collaboration Term. (b) Anacor hereby grants to GSK a non-exclusive, non-royalty bearing license under the Anacor IP, solely as and to the extent necessary or important to conduct activities for which GSK is responsible under the Research Plans during the Research Collaboration Term.

Research Collaboration. 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform A▇▇▇▇▇ of its decision in writing. If A▇▇▇▇▇▇▇ decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, A▇▇▇▇▇▇▇ decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If A▇▇▇▇▇▇▇ decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform A▇▇▇▇▇ of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 W...

Research Collaboration. 2.1 Upon the execution of this Agreement and the receipt from LPT of the necessary materials and information as specified in Paragraph 2.2, below, AERES will undertake the humanization of LPT’s Sphingomab™ antibody in accordance with the Research set forth in Annex A hereto. The Research Plan may be amended as mutually agreed to by the parties. The parties agree to use commercially reasonable efforts to perform their respective responsibilities under the Research Collaboration. 2.2 Under the Research Plan, AERES shall provide the following biological materials, data, information, and reports to LPT (collectively, the “AERES Deliverables”): (i) [Gene expression vector inserts incorporating Sphingomab™ heavy chain and light chain CDRs, one or more (if more than one is made by AERES) of each of (a) and (b) below:] (a) [Sphingomab™ human heavy chain framework region gene insert (but not the heavy chain expression vector) made by replacing the original human CDRs in the human heavy chain framework region with the Sphingomab mouse CDRs;] and (b) [Sphingomab™ human light chain framework region gene insert (but not the light chain expression vector) made by replacing the original human CDRs in the human light chain framework region with the Sphingomab mouse CDRs;] (ii) All data and reports relevant to the humanization of Sphingomab™ including, but not limited to data on antigen binding and expression levels. (iii) Final written reports setting forth in reasonable detail the results of AERES’s humanisation of LPT antibody Sphingomab™ including, without limitation, the structural and synthesis information (including, but not limited to, the DNA and amino acid sequence information) for all Humanised Antibodies. 2.3 After the Effective Date, LPT shall, at its expense and without charge to AERES, deliver to AERES at least one cell line that produces LPT’s Sphingomab™ antibody and such LPT know-how including related technical information as sufficient (in the reasonable judgment of both parties) to enable AERES to carry out its humanization obligations under this Agreement (the “LPT Deliverables”). The LPT Deliverables shall be deemed to be Confidential Information of LPT; provided, however, that the obligations hereunder of non-use and non-disclosure related to any LPT Deliverable shall continue for so long as such LPT Deliverable remains Confidential Information. The transfer from LPT to AERES of the cell line(s) producing LPT’s Sphingomab™ antibody is solely for the ...

Research Collaboration. Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

Research Collaboration. Subject to the terms and conditions set forth herein, University hereby agrees to use its best efforts to collaborate with XYZ in pursuing the Research Project and undertake its own responsibilities set forth in Schedule 2, provided that XYZ shall perform its own responsibilities set forth in Schedule 2.

Research Collaboration. 2.1 BDSI will provide to ***** soy-derived phosphatidylserine at its cost to manufacture the product. ***** will provide at least one process-sensitive ingredient, as well as manufacturing facilities and personnel to encochleate the process-sensitive ingredient with instruction and know how from BDSI and to incorporate the encochleated process-sensitive ingredient into a finished `food product. 2.2 BDSI and ***** will jointly conduct the Research Plan ("RP") outlined in Appendix A. 2.3 will pay all reasonable expenses associated with the RP as outlined in Appendix B.

Research Collaboration. GIT and <INSERT Abbreviated Name of Int’l School/Entity HERE> will initiate collaborative activities contingent upon successful negotiation and execution of appropriate agreements at a later date, which shall outline the terms and conditions applicable to each activity, and as GIT is permitted under U.S. export laws and regulations, and as <INSERT Abbreviated Name of Int’l School/Entity HERE> is permitted under its country’s laws. The Parties understand and agree that the Georgia Tech Research Corporation (GTRC) is a cooperative organization of GIT and shall enter into any research agreements on behalf of GIT. Joint research projects may be explored by appropriate faculty members with the approval of the Parties according to the established procedures at each institution.

Research Collaboration. 2.1 Upon the execution of this Agreement and the receipt from ACORDA of the necessary materials and information as specified in Article 2.2 below, AERES will undertake the class switching of ACORDA antibodies Lym22 and/or Lym46 together with the creation of a Stable Cell Line expressing each antibody in accordance with the Research Plan set forth in Annex A hereto. 2.2 ACORDA shall, at its expense and without charge to AERES, deliver to AERES ACORDA antibodies Lym22 and Lym46 and plasmids incorporating genes expressing said ACORDA antibodies and such Know-how including related technical information as sufficient (in the reasonable judgement of both parties) to enable AERES to carry out the Research Plan. AERES shall disclose to ACORDA all Know-how created or used in carrying out the Research Plan and shall make such disclosure only to ACORDA except as provided in Article VII. 2.3 AERES shall permit duly authorized employees of ACORDA to have access to AERES’s laboratories from time to time at mutually agreeable times and upon reasonable notice. 2.4 ACORDA shall obtain and retain all rights, title and interest in DNA and RNA sequences expressing ACORDA antibodies Lym22 and Lym46 and any and all cell lines (including Stable Cell Lines) expressing the same. AERES hereby assigns and agrees to assign all rights, title and interest in DNA and RNA sequences expressing ACORDA antibodies Lym22 and Lym46 and any and all cell lines (including Stable Cell Lines) expressing the same, and in all Inventions of AERES relating to any of the foregoing. Antibodies Lym22 and Lym46 and cell lines for their production will be maintained within the sole possession and control of AERES (other than transfer to ACORDA as contemplated herein), and will not be distributed, transferred or sold by AERES to any third party for any purpose whatsoever without the prior written consent of ACORDA. 2.5 AERES shall retain all rights, title and interest in antibody engineering techniques, gene expression vectors, materials and Know-how used or developed in the course of the Research Plan at Annex A, including the use of such vectors for the expression of any gene or gene construct other than DNA and RNA sequences encoding genes and gene constructs developed for ACORDA hereunder. In particular, information relating to antibody engineering techniques and gene expression vectors comprising Know-how used or developed by AERES in the course of the Research Plan at Annex A shall be (or remain) the c...